arrow
P

Philippe Follana

centre antoine lacassagne
H指数:30
被引数:6,981

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of renal and hepatic function on dihydropyrimidine dehydrogenase phenotype assessed by enzyme activity in peripheral blood mononuclear cells and uracilemia

肾功能和肝功能对通过外周血单核细胞酶活性和尿嘧啶血症评估的二氢嘧啶脱氢酶表型的影响

2025-09-010
PRE
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial

奥拉帕利维持治疗在铂类为基础化疗后的晚期/转移性子宫内膜癌中的应用:GINECO随机IIb期UTOLA试验

2025-08-260
OAAI
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database

无铂间期(PFI)及维持治疗在复发性卵巢癌中的作用:解释生存率的法国真实世界ESME卵巢数据库分析

2025-08-070
PRE
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer

NSGO-FANDANGO/ENGOT-EN1:一项关于在晚期/复发性子宫内膜癌中使用尼达尼布/安慰剂联合一线化疗的随机Ⅱ期研究

2025-06-300
PRE
Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe study

尼拉帕利在复发性卵巢癌维持治疗中的暴露-反应关系:法国GINECO-NiQoLe研究的附加分析

2025-05-010
PRE
Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial

奥拉帕利联合间质环磷酰胺和二甲双胍治疗复发性晚期/转移性子宫内膜癌的女性:ENDOLA I/II期试验

2025-02-200
OA
A Retrospective Multicentre Study To Evaluate The Impact Of Platinum-Free Interval On Progression-Free And Overall Survival In Patients With Recurrent Epithelial Ovarian Cancer, Using Real-World Data From The ESME Database

一项回顾性多中心研究,旨在评估无铂间隔对复发性上皮性卵巢癌患者无进展生存期和总生存期的影响,使用来自ESME数据库的真实世界数据。

2025-02-010
PRE
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)
2024-12-141
OAAI
Avelumab plus methotrexate to eradicate low-risk gestational trophoblastic tumors in first-line setting: TROPHAMET phase I/II trial

阿维鲁姆单抗联合甲氨蝶呤在一线治疗中根除低危妊娠滋养细胞肿瘤:TROPHAMET I/II期试验

2024-09-011
PRE
Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)

III期ATALANTE/ENGOT-ov29试验最终总生存期(OS)结果,该试验评估了在铂敏感复发的卵巢癌(OC)患者(pts)中,阿替利珠单抗(Atz)与安慰剂联合标准化疗(Cx)加贝伐珠单抗(bev)的比较。

2024-09-011
PRE
Initial management and long-term outcome of ovarian clear cell carcinoma (OCCC) in the French multicentre ESME database

法国多中心ESME数据库中卵巢透明细胞癌(OCCC)的初始管理和长期预后

2024-09-010
PRE
PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent
CANCER
IF5.1
2024-03-122
OAAI
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
LANCET
IF88.5
2024-01-0155
OAAI
Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
2023-10-011
OAAI
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

基于基线体重和血小板计数的尼拉帕尼给药的耐受性和疗效的前瞻性评估: PRIMA/ENGOT-OV26/GOG-3012试验的结果

CANCER
IF5.1
2023-04-1413
OAAI
Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study
2019-05-0137
OAAI